Navigate Fool.com
Will ACHN beat
the market?
Community Rating: 3 Stars: Appealing

2.77 -0.02 (-0.72%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.79
Previous Close $2.79
Daily Range $2.71 - $2.90
52-Week Range $2.26 - $8.49
Market Cap $268.1M
P/E Ratio -4.43
Dividend (Yield) $0.00 (0.0%)
Volume 432,599
Average Daily Volume 1,805,176
Current FY EPS -$0.77

How do you think ACHN
will perform against the market?

Top ACHN Bull/Bear Pitches


zzlangerhans (< 20)
Submitted July 2, 2010

As hard as it might seem to justify green-thumbing a company that sounds like a sneeze, I'm going to give it a shot anyway. In 2006 Achillion (bless you) stock maxed out at 20 on the strength of a pa … More

1 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted December 14, 2010

Achillion survived a 50M dilutive financing in August to rise significantly after the initiation of the phase II trial of ACH-1625. These events mean that Achillion will end the year with a comfortabl … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

3 Biotechs Bucking the Downtrend

Three biotech winners amid a sea of losers.

Noteworthy ETF Outflows: XBI, GERN, ACHN, EXAS

Why Herbalife, Steel Partners Holdings, and Achillion Pharmaceuticals Jumped Today

Monday was largely a down day for the stock market, as the once-flying biotech sector again weighed on the broader indexes. But these stocks jumped sharply. Find out why.

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Why Achillion Pharmaceuticals Inc. Shares Briefly Spiked Higher

Achillion shares jump after reporting intriguing data on hepatitis-C drug ACH-3102. Can Achillion shares head higher from here?

Pre-Market Most Active for Jan 9, 2014 : ALU, JCP, NOK, AV, BAC, C^K, ICPT, SQNM, FB, QQQ, ACHN, BB

Pre-Market Most Active for Jan 9, 2014 : ALU, JCP, NOK, AV, BAC, C^K, ICPT, SQNM, FB, QQQ, ACHN, BBBY

3 Most Horrendous Health-Care Stocks of 2013

Amarin, Ariad, and Achillion might all begin with the letter "A" -- but all three stocks earn "F" grades for 2013.

Insiders Buy Shares at Sigma Designs, Golub Capital, and Agree Realty

Achillion Pharmaceuticals sees a sale.

3 Biotech Flops of 2013

2013 was a great year for the biotech industry as a whole, but Achillion, Prosensa, and Amarin didn't share the joy.

3 Lessons From Amarin's Failures in 2013

Amarin had an awful 2013, being marginalized by GlaxoSmithKline’s Lovaza, upcoming generic competition from Teva, and a new treatment from AstraZeneca. What three valuable lessons can we learn from Amarin’s decline?

See More ACHN News...






A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases Website: http://www.achillion.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks